Dr. Charles Melbern Wilcox, MD

Dr. Wilcox practices at Orange Avenue Surgery Center in Orlando, Florida.

Dr. Wilcox's NPI, 1740297027, was assigned on August 1, 2006. Dr. Wilcox graduated from Medical College of Georgia in 1983. Dr. Wilcox's Alabama license number on file is 11632.

Dr. Wilcox's primary practice is Orange Avenue Surgery Center, at 1405 S Orange Ave Ste 120, Orlando, FL 32806. The practice phone is (321) 228-6700.

Dr. Wilcox's primary practice is Orange Avenue Surgery Center in Orlando, Florida. Dr. Wilcox is also affiliated with Orlando Regional Medical Center. The medical group on file is UAB Medicine. Dmand AI also links Dr. Wilcox to 3 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wilcox practices, 6 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Wilcox's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Wilcox is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Wilcox's licenses on file in 7 states: Alabama, California, Florida, Montana, Virginia, Indiana and Georgia.

CMS data shows 185 Medicare services from Dr. Wilcox across 6 procedure codes in 2024, for 170 Medicare patients. Medicare paid $18,473 for them.

CMS counts 170 Medicare patients who saw Dr. Wilcox in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wilcox's median patient age at 57, with 54% women.

In 2024, Dr. Wilcox wrote 233 Medicare Part D claims for 113 patients. 79% of them were for generic drugs. CMS names the drug for 135 of them, across 5 drugs with 11 or more claims each, at $89,432 in total drug cost. In 2023, CMS named 42 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Wilcox for performance year 2024, reported as part of a group. Dr. Wilcox accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wilcox as offering telehealth. CMS counts 29 procedures of colonoscopy by Dr. Wilcox, more than 53% of the clinicians it reports for that procedure.

Dmand AI links 297 papers to Dr. Wilcox, published from 2002 to 2023. 2014 was the busiest year, with 18. The most frequent topics are Cholangiopancreatography, Endoscopic Retrograde, Gastrointestinal Hemorrhage and AIDS-Related Opportunistic Infections. Dr. Wilcox has published most often in Gastrointest Endosc. Dr. Wilcox's most frequent co-authors are Shyam S. Varadarajulu, MD, Shajan Peter and Christopher E. Forsmark, MD.

Dmand AI links Dr. Wilcox to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Pancreatitis, Pancreatitis, Chronic and Duodenal Neoplasms. University of Alabama at Birmingham sponsors the most, 2.

CMS Open Payments shows 45 general payments to Dr. Wilcox from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $348.

Dmand AI lists 23 awards for Dr. Wilcox, most recently Patients’ Choice Award in 2014.

Dr. Wilcox graduated from Medical College of Georgia in 1983.

Dr. Wilcox is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.